Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 9.768
- Book/Share 2.5668
- PB 13.8539
- Debt/Equity 1.9244
- CurrentRatio 1.8751
- ROIC 0.0638
- MktCap 7797272884.0
- FreeCF/Share 0.5811
- PFCF 59.2782
- PE 60.1611
- Debt/Assets 0.5006
- DivYield 0
- ROE 0.2467
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | HIMS | Barclays | -- | Overweight | -- | $48 | Dec. 9, 2025 |
| Initiation | HIMS | KeyBanc Capital Markets | -- | Sector Weight | -- | -- | Oct. 21, 2025 |
| Downgrade | HIMS | Needham | Buy | Hold | -- | -- | June 23, 2025 |
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
These 5 Stocks Are Set To Dominate 2026
Published: December 19, 2025 by: Seeking Alpha
Sentiment: Positive
My 2025 picks outperformed the S&P 500 by 9.4% and Nasdaq 100 by 5.9%, validating my growth-value approach. Each stock on this list is operating in a different market segment and two are based in Europe, offering geographic diversification. The featured stocks all show significant undervaluation potential based on rather conservative growth scenarios.
Read More
3 Skyrocketing MedTech Stocks That Might Lose Steam in 2026
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Here are some surging MedTech stocks - GMED, TMDX and HIMS - that may face slowing momentum in 2026.
Read More
Hims & Hers Scales Technology-Driven Care as Profitability Evolves
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS scales personalized care, expands globally and invests in technology as it balances growth with evolving profitability.
Read More
Hims & Hers Expands Weight-Management Program to the United Kingdom
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS expands its Weight Loss Program to the United Kingdom, bringing personalized, doctor-designed care and broader access to obesity treatments.
Read More
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Read More
Hims & Hers Expands Its Technology-Driven Personalized Virtual Care
Published: December 11, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS expands its tech-driven care with new diagnostics, hormonal treatments, and a Canada launch via Livewell.
Read More
Hims & Hers Plunges 29.1% in 6 Months: Time to Hold the Stock or Sell?
Published: December 09, 2025 by: Zacks Investment Research
Sentiment: Negative
HIMS expands into Canada and Europe while facing regulatory hurdles and execution risks in weight-loss care.
Read More
OMCL vs. HIMS: Which Stock Should Value Investors Buy Now?
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Hims & Hers launches into Canada as country prepare for generic GLP-1 weight loss drugs
Published: December 04, 2025 by: CNBC Television
Sentiment: Positive
Hims & Hers launched in Canada after announcing the company completed its all-cash acquisition of Canadian digital health provider “Livewell”. The deal comes just one month before generic semaglutide weight loss drugs come to market in the country.
Read More
HIMS Stock Jumps After Buyout Deal, Boosts Blood Collection Efficiency
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers is set to acquire YourBio Health, adding bladeless microneedle tech to transform the blood collection experience.
Read More
Hims & Hers shares jump on expansion into Canada
Published: December 04, 2025 by: Proactive Investors
Sentiment: Positive
US-based digital health company Hims & Hers Holdings Inc (NYSE:HIMS) is entering the Canadian market following its acquisition of Livewell, a Canadian telehealth platform focused on weight loss and other wellness services. The move positions Hims & Hers to launch a Canadian weight loss program in 2026, coinciding with the availability of the first generic semaglutide.
Read More
Hims & Hers Expands Care Scope as Prescription Platforms Evolve
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS grows its telehealth-to-prescription model with new offerings in weight loss, hormone care and diagnostics.
Read More
Here is What to Know Beyond Why Hims & Hers Health, Inc. (HIMS) is a Trending Stock
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
HIMS vs. GDRX: Which Consumer Health Stock Offers Greater Upside?
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers and GoodRx are reshaping virtual care, but which one leads in platform strategy and patient engagement? Let's dive in.
Read More
From Hair Loss To GLP-1: Hims & Hers Health Is Quietly Building A 2030 Healthcare Platform
Published: November 25, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health, Inc. (HIMS) presents a compelling risk-reward profile as bearish sentiment and regulatory concerns appear fully priced into the stock. HIMS is aggressively expanding its product offerings and logistics, driving subscriber and revenue growth, despite near-term margin compression and increased capital expenditures. The upcoming Zava acquisition and potential regulatory changes could further boost HIMS's international presence and revenue, with DCF-based valuations suggesting significant upside.
Read More
Hims & Hers Expands Care Scope as Digital Health Platforms Evolve
Published: November 25, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS expands into low testosterone and menopause care, with plans for longevity and global growth in 2026.
Read More
Hims & Hers Accelerates Its Clinician-Led, Platform-Driven Care Model
Published: November 21, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS expands its connected care model with new diagnostics, hormonal health services and at-home testosterone treatments.
Read More
OMCL or HIMS: Which Is the Better Value Stock Right Now?
Published: November 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical Info Systems sector might want to consider either Omnicell (OMCL) or Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Hims & Hers Plunges 15.6% in 3 Months: Time to Hold the Stock or Sell?
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
HIMS faces rising regulatory strain, margin pressure and competition despite strong revenue momentum.
Read More
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Published: November 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Read More
Il Makiage parent Oddity takes aim at Hims with new telehealth skincare platform Methodiq
Published: November 18, 2025 by: CNBC
Sentiment: Positive
Oddity, the maker of Il Makiage and Spoiled Child, launched its third brand Methodiq, a telehealth platform for medical skincare. Methodiq will offer 28 new products, including creams, supplements and cosmetics, that address acne, hyperpigmentation and eczema and range in price from about $29 to around $59.
Read More
Hims & Hers Bets on Lab Testing to Boost Growth
Published: November 13, 2025 by: WSJ
Sentiment: Positive
The telehealth platform expects the new offering to add to its user base as it draws customers looking to prevent future health issues.
Read More
Hims & Hers Scales Technology-Enabled, Vertically Integrated Care
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
HIMS deepens its technology-enabled care model with new offerings in GLP-1 weight loss, hormone health, and custom treatments.
Read More
3 Overvalued Stocks to Sell
Published: November 11, 2025 by: Morningstar
Sentiment: Negative
These are among the most overvalued stocks that Morningstar covers.
Read More
Hims & Hers: Fast-Fashion Healthcare Is The Future (Rating Upgrade)
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Positive
We're turning bullish on Hims & Hers now that we believe the worst is priced in. Q3 results confirm that the growth story remains centered around personalized plans driving 50% Y/Y revenue growth. Hence, it see longer-term financial leverage from scaling that business model. The "active discussions" with Novo Nordisk are a cherry on top but we see green shoots outside of weight-loss drugs that'll support growth.
Read More
Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS expands its AI-powered, subscription-based care model globally, backed by $870 million in fresh funding for growth.
Read More
Is Most-Watched Stock Hims & Hers Health, Inc. (HIMS) Worth Betting on Now?
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Hims & Hers Stock Slips Post Y/Y Q3 Earnings Decline, Margins Contract
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
HIMS reports lower third-quarter 2025 earnings even as revenue and subscriber growth remain strong across its channels.
Read More
Why Hims & Hers Stock May Be a Buy After Mixed Q3 Results
Published: November 05, 2025 by: MarketBeat
Sentiment: Neutral
Hims & Hers Health Inc. NYSE: HIMS stock is holding onto a slight gain the day after the company delivered a mixed third-quarter earnings report. The caution centers around the company's valuation, which makes it an outlier among healthcare stocks.
Read More
OMCL vs. HIMS: Which Stock Is the Better Value Option?
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Medical - Equipment & Services
- CEO Andrew Dudum
- Employees 1637